Ireland
--:--IST
Active, not recruiting Observational

Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

NCT05103605 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2021-05-12
Last updated
2025-12-01

Condition(s) studied

Non Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Osimertinib →

Osimertinib: Single arm treated by osimertinib

Study summary

This is an observational multicenter study. A cross-sectional descriptive study of patients with locally advanced or metastatic Non Small Cell Lung Cancer with activating EGFR mutation treated by any first line therapy will be used to identify cohort with a prospective follow-up of patients initiating a treatment by osimertinib in first line

* A cross-sectional descriptive study of all patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated by any first line therapy will be collected at the study participating sites. The study which is transversal will allow to characterize the population of patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated in first line, the day of first line initiation.
* Additionally, a prospective study targeting a cohort of patients focusing on patients with locally advanced or metastatic NSCLC with activating EGFR mutation initiating a treatment by osimertinib in first line will be conducted to address describe in real life conditions the 36-months overall survival, patients baseline characteristics, disease evolution, sequencing and treatment patterns, and quality of life

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Descriptive cross-sectional survey (Population B) * Adult patients (≥ 18 years old), * Patients newly treated in first line (1L) for locally advanced or metastatic NSCLC, * Patients with activating EGFR mutation-positive, * Patient informed and not opposed to these data collection. * Prospective cohort (Population A) * Patient meeting part B inclusion criteria, * Patients newly treated in 1L by osimertinib, * Patient with common EGFR mutation-positive (exon 19 deletion or L858R mutation, alone or co-occuring with other EGFR mutations). Exclusion Criteria (Population A): * Patients enrolled in interventional clinical trials (first line treatment for a NSCLC) during the study period.

Primary outcome measure(s)

  • Overall survival — 36 months
    36-months overall survival defined as time from index date until death from any cause

Trial sites (46)

FacilityCityRegionStatus
Research Site Abbeville France
Research Site Aix-en-Provence France
Research Site Angers France
Research Site Antibes France
Research Site Avignon France
Research Site Bastia France
Research Site Bayonne France
Research Site Bordeaux France
Research Site Bourg-en-Bresse France
Research Site Brest France
Research Site Cannes France
Research Site Chambéry France
Research Site Chauny France
Research Site Cholet France
Research Site Clermont-Ferrand France
Research Site Colmar France
Research Site Contamine-sur-Arve France
Research Site Créteil France
Research Site Elbeuf France
Research Site Epagny METZ Tessy France
Research Site Évreux France
Research Site La Roche-sur-Yon France
Research Site Libourne France
Research Site Limoges France
Research Site Lyon France
Research Site Marseille France
Research Site Meaux France
Research Site Mulhouse France
Research Site Orléans France
Research Site Paris France
Research Site Poitiers France
Research Site Quimper France
Research Site Reims France
Research Site Rouen France
Research Site Saint-Denis France
Research Site Saint-Grégoire France
Research Site Saint-Pierre France
Research Site Saint-Priest-en-Jarez France
Research Site Saint-Quentin France
Research Site Toulon France

+ 6 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05103605 on ClinicalTrials.gov ↗ ← All trials in France